These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 20395444)

  • 1. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
    Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
    Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
    Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
    PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
    Geyer FC; Lacroix-Triki M; Savage K; Arnedos M; Lambros MB; MacKay A; Natrajan R; Reis-Filho JS
    Mod Pathol; 2011 Feb; 24(2):209-31. PubMed ID: 21076461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
    Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
    Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
    Prasad CP; Gupta SD; Rath G; Ralhan R
    Oncology; 2007; 73(1-2):112-7. PubMed ID: 18337623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.
    Wend P; Runke S; Wend K; Anchondo B; Yesayan M; Jardon M; Hardie N; Loddenkemper C; Ulasov I; Lesniak MS; Wolsky R; Bentolila LA; Grant SG; Elashoff D; Lehr S; Latimer JJ; Bose S; Sattar H; Krum SA; Miranda-Carboni GA
    EMBO Mol Med; 2013 Feb; 5(2):264-79. PubMed ID: 23307470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
    Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
    PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.
    Prosperi JR; Goss KH
    Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
    Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
    Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast.
    Prasad CP; Mirza S; Sharma G; Prashad R; DattaGupta S; Rath G; Ralhan R
    Life Sci; 2008 Aug; 83(9-10):318-25. PubMed ID: 18662704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
    López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis.
    Klemm F; Bleckmann A; Siam L; Chuang HN; Rietkötter E; Behme D; Schulz M; Schaffrinski M; Schindler S; Trümper L; Kramer F; Beissbarth T; Stadelmann C; Binder C; Pukrop T
    Carcinogenesis; 2011 Mar; 32(3):434-42. PubMed ID: 21173432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
    Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
    PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    Hou MF; Chen PM; Chu PY
    BMC Cancer; 2018 Feb; 18(1):219. PubMed ID: 29471794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.
    Tan Z; Zheng H; Liu X; Zhang W; Zhu J; Wu G; Cao L; Song J; Wu S; Song L; Li J
    Oncotarget; 2016 Apr; 7(17):24076-87. PubMed ID: 26992223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of regulatory miRNAs of the Wnt/ β-catenin signaling pathway in tumorigenesis of breast cancer.
    Rahmani F; Tadayyon Tabrizi A; Hashemian P; Alijannejad S; Rahdar HA; Ferns GA; Hassanian SM; Shahidsales S; Avan A
    Gene; 2020 Sep; 754():144892. PubMed ID: 32534060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.